DOCA-Salt Hypertension: an Update

Current Hypertension Reports

Volumn 19, Issue 4, 2017, Pages

  Basting, Tyler ^a,b   Lazartigues, Eric ^a,b,c  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Cardiovascular; DOCA salt; Immune; Neurogenic hypertension; Neurohormonal; Renal

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN I; ANGIOTENSIN II; CAPTOPRIL; GAMMA INTERFERON; INTERLEUKIN 17; LOSARTAN; PRORENIN RECEPTOR; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR; VASOPRESSIN; DEOXYCORTICOSTERONE ACETATE;

ALDOSTERONE RELEASE; AUTONOMIC DENERVATION; AUTONOMIC NERVOUS SYSTEM; BLOOD PRESSURE REGULATION; DEOXYCORTICOSTERONE-SALT INDUCED HYPERTENSION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE MASS; HEART OUTPUT; HEART STROKE VOLUME; HUMAN; HYPERVOLEMIA; INFLAMMATION; NONHUMAN; PRESSORECEPTOR REFLEX; PROTEIN EXPRESSION; RECEPTOR BINDING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RODENT MODEL; SODIUM BALANCE; SODIUM RETENTION; SYMPATHETIC REFLEX; T LYMPHOCYTE; VASCULAR RESISTANCE; VASOPRESSIN RELEASE; ANIMAL; BLOOD PRESSURE; HYPERTENSION; KIDNEY; PATHOPHYSIOLOGY; SALT INTAKE;

ANIMALS; BLOOD PRESSURE; DESOXYCORTICOSTERONE ACETATE; HUMANS; HYPERTENSION; KIDNEY; SODIUM CHLORIDE, DIETARY;

EID: 85016412798     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-017-0731-4     Document Type: Review

References (80)

1. Carretero OA, Oparil S. Essential hypertension part I: definition and etiology. Circulation. 2000:329–35
2. Guyenet PG. The sympathetic control of blood pressure. Nat Rev Neurosci. 2006;7(5):335–46.
3. Drenjancevic-Peric I, Jelakovic B, Lombard JH, Kunert MP, Kibel A, Gros M. High-salt diet and hypertension: focus on the renin-angiotensin system. Kidney Blood Press Res. 2011;34(1):1–11. doi:10.1159/000320387.
4. Zicha J, Kunes J, Lebl M, Pohlova I, Slaninova J, Jelinek J. Antidiuretic and pressor actions of vasopressin in age-dependent DOCA-salt hypertension. Am J Phys. 1989;256(1 Pt 2):R138–45.
5. Anderson PG, Bishop SP, Digerness SB. Coronary vascular function and morphology in hydralazine treated DOCA salt rats. J Mol Cell Cardiol. 1988;20(10):955–67.
6. • Xia H, Sriramula S, Chhabra K, Lazartigues E. Brain ACE2 shedding contributes to the development of neurogenic hypertension. Circ Res. 2013;113:1087–96. This study highlights how ACE2 and Ang1-7 are downregulated in hypertension and could be major beneficial players in future therapeutics.
7. • Grobe JL, Buehrer BA, Hilzendeger AM, Liu X, Davis DR, Xu D, et al. Angiotensinergic signaling in the brain mediates metabolic effects of deoxycorticosterone (DOCA)-salt in C57 mice. Hypertension. 2011;57(3):600–7. doi:10.1161/hypertensionaha.110.165829. This emphasizes the critical players in the CNS contributing to DOCA-salt hypertension.
8. Weinberger MH, Miller JZ, Luft FC, Grim CE, Fineberg NS. Definitions and characteristics of sodium sensitivity and blood pressure resistance. Hypertension. 1986;8(6 Pt 2):II127–34.
9. Poch E, Gonzalez D, Giner V, Bragulat E, Coca A, de La Sierra A. Molecular basis of salt sensitivity in human hypertension. Evaluation of renin-angiotensin-aldosterone system gene polymorphisms. Hypertension. 2001;38(5):1204–9.
10. Funder J, New MI. Low renin hypertension (LRH): shades of John Laragh. Trends Endocrinol Metab. 2008;19(3):83. doi:10.1016/j.tem.2008.01.008.
11. Turkkan JS, Goldstein DS. Production and reversal of DOCA-salt hypertension in baboons. Clin Exp Hypertens A. 1987;9(1):125–40.
12. Abrams JM, Engeland WC, Osborn JW. Effect of intracerebroventricular benzamil on cardiovascular and central autonomic responses to DOCA-salt treatment. Am J Physiol Regul Integr Comp Physiol. 2010;299(6):R1500–10. doi:10.1152/ajpregu.00431.2010.
13. • Dampney RA. Central neural control of the cardiovascular system: current perspectives. Adv Physiol Educ. 2016;40(3):283–96. doi:10.1152/advan.00027.2016. A detailed review of the cardiovascular and circulatory components involved in the pathogenesis of hypertension.
14. Takeda K, Nakamura Y, Hayashi J, Kawasaki S, Nakata T, Oguro M, et al. Effects of salt and DOCA on hypothalamic and baroreflex control of blood pressure. Clin Exp Hypertens A. 1988;10(Suppl 1):289–99.
15. •• Takeda K, Nakamura Y, Oguro M, Kawasaki S, Hayashi J, Tanabe S, et al. Central attenuation of baroreflex precedes the development of hypertension in DOCA-salt-treated rats. Am J Hypertens. 1988;1(3 Pt 3):23S–5S. An early study showing that changes in the central nervous system predate those in the periphery in the pathogenesis of hypertension.
16. O'Donaughy TL, Brooks VL. Deoxycorticosterone acetate-salt rats: hypertension and sympathoexcitation driven by increased NaCl levels. Hypertension. 2006;47(4):680–5. doi:10.1161/01.HYP.0000214362.18612.6e.
17. Scrogin KE, Grygielko ET, Brooks VL. Osmolality: a physiological long-term regulator of lumbar sympathetic nerve activity and arterial pressure. Am J Phys. 1999;276(6 Pt 2):R1579–86.
18. Weinberger MH, Fineberg NS, Fineberg SE, Weinberger M. Salt sensitivity, pulse pressure, and death in normal and hypertensive humans. Hypertension. 2001;37(2 Pt 2):429–32.
19. Fink GD, Johnson RJ, Galligan JJ. Mechanisms of increased venous smooth muscle tone in desoxycorticosterone acetate-salt hypertension. Hypertension. 2000;35(1 Pt 2):464–9.
20. Fink GD, Pawloski CM, Blair ML, Mangiapane ML. The area postrema in deoxycorticosterone-salt hypertension in rats. Hypertension. 1987;9(6 Pt 2):III206–9.
21. Berecek KH, Barron KW, Webb RL, Brody MJ. Vasopressin-central nervous system interactions in the development of DOCA hypertension. Hypertension. 1982;4(3 Pt 2):131–7.
22. Ciriello J. Contribution of forebrain mechanisms in the maintenance of deoxycorticosterone acetate-salt hypertension. Clin Exp Hypertens A. 1988;10(Suppl 1):169–78.
23. Bruner CA, Mangiapane ML, Fink GD, Webb RC. Area postrema ablation and vascular reactivity in deoxycorticosterone-salt-treated rats. Hypertension. 1988;11(6 Pt 2):668–73.
24. Fink GD, Bruner CA, Mangiapane ML. Area postrema is critical for angiotensin-induced hypertension in rats. Hypertension. 1987;9:355–61.
25. Ueno Y, Mohara O, Brosnihan KB, Ferrario CM. Characteristics of hormonal and neurogenic mechanisms of deoxycorticosterone-induced hypertension. Hypertension. 1988;11(2 Pt 2):I172–7.
26. Hamlyn JM, Blaustein MP. Sodium chloride, extracellular fluid volume, and blood pressure regulation. Am J Phys. 1986;251(4 Pt 2):F563–75.
27. Falcon JC, Phillips MI, Hoffman WE, Brody MJ. Effects of intraventricular angiotensin II mediated by the sympathetic nervous system. Am J Phys. 1978;235:H392–H9.
28. Esler M, Kaye D. Sympathetic nervous system activation in essential hypertension, cardiac failure and psychosomatic heart disease. J Cardiovasc Pharmacol. 2000;35(7 Suppl. 4):S1–7.
29. Albrecht vBuHOD. The CNS renin-angiotensin system 2006.
30. Chapleau MW, Abboud FM. Neuro-cardiovascular regulation: from molecules to man. Ann NY Acad Sci. 2001:1. New York.
31. Gutkind JS, Kurihara M, Saavedra JM. Increased angiotensin II receptors in brain nuclei of DOCA-salt hypertensive rats. Am J Hypertens. 1988;255(3 Pt 2):H646–H50.
32. Mangiapane ML, Simpson JB. Subfornical organ lesions reduce the pressor effect of systemic angiotensin II. Neuroendocrinology. 1980;31(6):380–4.
33. Li W, Liu J, Hammond SL, Tjalkens RB, Saifudeen Z, Feng Y. Angiotensin II regulates brain (pro)renin receptor expression through activation of cAMP response element-binding protein. Am J Physiol Regul Integr Comp Physiol. 2015;309(2):R138–47. doi:10.1152/ajpregu.00319.2014.
34. Chan JY, Wang LL, Lee HY, Chan SH. Augmented upregulation by c-fos of angiotensin subtype 1 receptor in nucleus tractus solitarii of spontaneously hypertensive rats. Hypertension. 2002;40(3):335–41.
35. Hilzendeger AM, Morgan DA, Brooks L, Dellsperger D, Liu X, Grobe JL, et al. A brain leptin-renin angiotensin system interaction in the regulation of sympathetic nerve activity. Am J Physiol Heart Circ Physiol. 2012;303(2):H197–206. doi:10.1152/ajpheart.00974.2011.
36. Park CG, Leenen FH. Effects of centrally administered losartan on deoxycorticosterone-salt hypertension rats. J Korean Med Sci. 2001;16(5):553–7.
37. Somers MJ, Mavromatis K, Galis ZS, Harrison DG. Vascular superoxide production and vasomotor function in hypertension induced by deoxycorticosterone acetate-salt. Circulation. 2000;101(14):1722–8.
38. Basso N, Ruiz P, Kurnjek ML, Cannata MA, Taquini AC. The brain renin-angiotensin system and the development of DOC-salt hypertension. Clin Exp Hypertens A. 1985;7(9):1259–68.
39. Tada Y, Wada K, Shimada K, Makino H, Liang EI, Murakami S, et al. Roles of hypertension in the rupture of intracranial aneurysms. Stroke. 2014;45(2):579–86. doi:10.1161/STROKEAHA.113.003072.
40. Basso N, Ruiz P, Mangiarua E, Taquini AC. Renin-like activity in the rat brain during the development of DOC-salt hypertension. Hypertension. 1981;3(6 Pt 2):II-14-7.
41. Itaya Y, Suzuki H, Matsukawa S, Kondo K, Saruta T. Central renin-angiotensin system and the pathogenesis of DOCA-salt hypertension in rats. Am J Phys. 1986;251(2 Pt 2):H261–H8.
42. Danser AH. The role of the (pro)renin receptor in hypertensive disease. Am J Hypertens. 2015;28(10):1187–96. doi:10.1093/ajh/hpv045.
43. Li W, Sullivan MN, Zhang S, Worker CJ, Xiong Z, Speth RC, et al. Intracerebroventricular infusion of the (pro)renin receptor antagonist PRO20 attenuates deoxycorticosterone acetate-salt-induced hypertension. Hypertension. 2015;65(2):352–61. doi:10.1161/HYPERTENSIONAHA.114.04458.
44. Li W, Peng H, Mehaffey EP, Kimball CD, Grobe JL, van Gool JM, et al. Neuron-specific (pro)renin receptor knockout prevents the development of salt-sensitive hypertension. Hypertension. 2014;63(2):316–23. doi:10.1161/HYPERTENSIONAHA.113.02041.
45. Feng Y, Xia H, Cai Y, Halabi CM, Becker LK, Santos RAS, et al. Brain-selective overexpression of human angiotensin-converting enzyme type 2 attenuates neurogenic hypertension. Circ Res. 2010;106(2):373–82. doi:10.1161/circresaha.109.208645.
46. Xu P, Sriramula S, Lazartigues E. ACE2/Ang-(1-7)/Mas pathway in the brain: the axis of good. Am J Physiology-Regul Integr Comp Physiol. 2011;300(4):R804–17. doi:10.1152/ajpregu.00222.2010.
47. Ferrario CM. ACE2: more of Ang-(1-7) or less Ang II? Curr Opin Nephrol Hypertens. 2011;20(1):1–6.
48. Lange DL, Haywood JR, Hinojosa-Laborde C. Endothelin enhances and inhibits adrenal catecholamine release in deoxycorticosterone acetate-salt hypertensive rats. Hypertension. 2000;35(1 Pt 2):385–90.
49. de Champlain J, Eid H, Papin D. Potentiated endothelin-1-induced phosphoinositide hydrolysis in atria and mesenteric artery of DOCA-salt hypertensive rats. J Hypertens Suppl. 1989;7(6):S136–7.
50. Lange DL, Haywood JR, Hinojosa-Laborde C. Role of the adrenal medullae in male and female DOCA-salt hypertensive rats. Hypertension. 1998;31(1 Pt 2):403–8.
51. Moreau P, Drolet G, Yamaguchi N, de Champlain J. Role of presynaptic beta 2-adrenergic facilitation in the development and maintenance of DOCA-salt hypertension. Am J Hypertens. 1993;6(12):1016–24.
52. Hofbauer KG, Studer W, Mah SC, Michel JB, Wood JM, Stalder R. The significance of vasopressin as a pressor agent. J Cardiovasc Pharmacol. 1984;6(Suppl 2):S429–38.
53. Mohring J, Mohring B, Petri M, Haack D. Vasopressor role of ADH in the pathogenesis of malignant DOC hypertension. Am J Phys. 1977;232(3):F260–9.
54. Mimura Y, Ogura T, Yamauchi T, Otsuka F, Oishi T, Harada K, et al. Effect of vasopressin V1- and V2-receptor stimulation on blood pressure in DOCA-salt hypertensive rats. Acta Med Okayama. 1995;49(4):187–94.
55. Rao MR. Effects of tetrandrine on cardiac and vascular remodeling. Acta Pharmacol Sin. 2002;23(12):1075–85.
56. Lee LK, Kim MY, Kim JH, Lee JU, Park BS, Yang SM, et al. A review of deoxycorticosterone acetate-salt hypertension and its relevance for cardiovascular physiotherapy research. J Phys Ther Sci. 2015;27(1):303–7. doi:10.1589/jpts.27.303.
57. Reiter U, Reiter G, Manninger M, Adelsmayr G, Schipke J, Alogna A, et al. Early-stage heart failure with preserved ejection fraction in the pig: a cardiovascular magnetic resonance study. J Cardiovasc Magn Reson. 2016;18(1):63. doi:10.1186/s12968-016-0283-9.
58. Moreno MU, Eiros R, Gavira JJ, Gallego C, Gonzalez A, Ravassa S, et al. The hypertensive myocardium: from microscopic lesions to clinical complications and outcomes. Med Clin North Am. 2017;101(1):43–52. doi:10.1016/j.mcna.2016.08.002.
59. Koito H, Yutaka H. CT and MRI findings of pulmonary hypertension. Nihon Rinsho. 2001;59(6):1107–12.
60. Bright R. Observations on the treatment of fever. Case of simple fever, protracted by irritation of the bowels, and attended by relapse. Guy's Hospital Reports. 1836;1:1–8.
61. • Coffman TM. The inextricable role of the kidney in hypertension. J Clin Invest. 2014;124(6):2341–7. doi:10.1172/JCI72274. A brief review that touches upon multiple alterations of the kidney during hypertension, including some mechanistic and physiological findings.
62. Mullins LJ, Conway BR, Menzies RI, Denby L, Mullins JJ. Renal disease pathophysiology and treatment: contributions from the rat. Dis Model Mech. 2016;9(12):1419–33. doi:10.1242/dmm.027276.
63. Pavlov TS, Staruschenko A. Involvement of ENaC in the development of salt-sensitive hypertension. Am J Physiol Renal Physiol. 2016; doi:10.1152/ajprenal.00427.2016.
64. Yemane H, Busauskas M, Burris SK, Knuepfer MM. Neurohumoral mechanisms in deoxycorticosterone acetate (DOCA)-salt hypertension in rats. Exp Physiol. 2010;95(1):51–5. doi:10.1113/expphysiol.2008.046334.
65. Kandlikar SS, Fink GD. Splanchnic sympathetic nerves in the development of mild DOCA-salt hypertension. Am J Physiol Heart Circ Physiol. 2011;301(5):H1965–73. doi:10.1152/ajpheart.00086.2011.
66. Kandlikar SS, Fink GD. Mild DOCA-salt hypertension: sympathetic system and role of renal nerves. Am J Physiol Heart Circ Physiol. 2011;300(5):H1781–7. doi:10.1152/ajpheart.00972.2010.
67. Banek CT, Knuepfer MM, Foss JD, Fiege JK, Asirvatham-Jeyaraj N, Van Helden D, et al. Resting afferent renal nerve discharge and renal inflammation: elucidating the role of afferent and efferent renal nerves in deoxycorticosterone acetate salt hypertension. Hypertension. 2016;68(6):1415–23. doi:10.1161/HYPERTENSIONAHA.116.07850.
68. Mahfoud F, Brilakis N, Bohm M, Narkiewicz K, Ruilope L, Schlaich M, et al. TCT-761 long-term (3-year) safety and effectiveness from the Global SYMPLICITY Registry of renal denervation in a real world patient population with uncontrolled hypertension. J Am Coll Cardiol. 2016;68(18S):B308. doi:10.1016/j.jacc.2016.09.791.
69. Warchol-Celinska E, Januszewicz A, Prejbisz A, Kadziela J. Renal denervation after the symplicity HTN-3 trial. Postepy Kardiol Interwencyjnej. 2014;10(2):75–7. doi:10.5114/pwki.2014.43509.
70. Rohrwasser A, Morgan T, Dillon HF, Zhao L, Callaway CW, Hillas E, et al. Elements of a paracrine tubular renin-angiotensin system along the entire nephron. Hypertension. 1999;34(6):1265–74.
71. Liu L, Gonzalez AA, McCormack M, Seth DM, Kobori H, Navar LG, et al. Increased renin excretion is associated with augmented urinary angiotensin II levels in chronic angiotensin II-infused hypertensive rats. Am J Physiol Renal Physiol. 2011;301(6):F1195–201. doi:10.1152/ajprenal.00339.2011.
72. Song K, Stuart D, Abraham N, Wang F, Wang S, Yang T, et al. Collecting duct renin does not mediate DOCA-salt hypertension or renal injury. PLoS One. 2016;11(7):e0159872. doi:10.1371/journal.pone.0159872.
73. Malik KU, Jennings BL, Yaghini FA, Sahan-Firat S, Song CY, Estes AM, et al. Contribution of cytochrome P450 1B1 to hypertension and associated pathophysiology: a novel target for antihypertensive agents. Prostaglandins Other Lipid Mediat. 2012;98(3–4):69–74. doi:10.1016/j.prostaglandins.2011.12.003.
74. Harrison D. Sy 17-2 inflammation, immunity and hypertension. J Hypertens. 2016;34(Suppl 1- ISH 2016 Abstract Book):e535. doi:10.1097/01.hjh.0000501473.77203.33.
75. •• Marvar PJ, Thabet SR, Guzik TJ, Lob HE, McCann LA, Weyand C, et al. Central and peripheral mechanisms of T-lymphocyte activation and vascular inflammation produced by angiotensin II-induced hypertension. Circ Res. 2010;107(2):263–70. doi:10.1161/CIRCRESAHA.110.217299. This study examines the role of the immune system in the development of hypertension and the necessity of T cells to disease pathogenesis
76. Dikalov SI, Nazarewicz RR, Bikineyeva A, Hilenski L, Lassegue B, Griendling KK, et al. Nox2-induced production of mitochondrial superoxide in angiotensin II-mediated endothelial oxidative stress and hypertension. Antioxid Redox Signal. 2014;20(2):281–94. doi:10.1089/ars.2012.4918.
77. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, et al. Role of the T cell in the genesis of angiotensin II-induced hypertension and vascular dysfunction. J Exp Med. 2007;204(10):2449–60. doi:10.1084/jem.20070657.
78. Krishnan SM, Dowling JK, Ling YH, Diep H, Chan CT, Ferens D, et al. Inflammasome activity is essential for one kidney/deoxycorticosterone acetate/salt-induced hypertension in mice. Br J Pharmacol. 2016;173(4):752–65. doi:10.1111/bph.13230.
79. Youn JC. Sy 17-3 role of cmv induced T cell senescence in the pathophysiology of cardiovascular disease. J Hypertens. 2016;34(Suppl 1- ISH 2016 Abstract Book):e535. doi:10.1097/01.hjh.0000501474.77203.fd.
80. Pinto YM, Paul M, Ganten D. Lessons from rat models of hypertension: from Goldblatt to genetic engineering. Cardiovasc Res. 1998;39(1):77–88.